Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antibody that functions as an antagonist by selectively targeting and binding to LILRB2. This interaction inhibits LILRB2 from associating with its natural ligands, including both classical and non-classical MHC class I molecules. By preventing LILRB2 from binding to HLA-A/B and HLA-G, which are markers of immunotolerance on tumor cells, Polzastobart effectively disrupts this inhibitory signal and enhances the production of pro-inflammatory cytokines in macrophages. This mechanism classifies Polzastobart as a macrophage immune checkpoint inhibitor, making it a critical tool in cancer immunotherapy research.
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antibody that functions as an antagonist by selectively targeting and binding to LILRB2. This interaction inhibits LILRB2 from associating with its natural ligands, including both classical and non-classical MHC class I molecules. By preventing LILRB2 from binding to HLA-A/B and HLA-G, which are markers of immunotolerance on tumor cells, Polzastobart effectively disrupts this inhibitory signal and enhances the production of pro-inflammatory cytokines in macrophages. This mechanism classifies Polzastobart as a macrophage immune checkpoint inhibitor, making it a critical tool in cancer immunotherapy research.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
